An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) has announced its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida on March 7, 2023. Douglas Bryant, the company’s president and CEO, will engage in a fireside chat at 11:35 a.m. ET / 8:35 a.m. PT. Investors can access a live webcast and replay on the company’s Investor Relations page. QuidelOrtho is a leader in in vitro diagnostics, committed to enhancing patient outcomes globally.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023.
Douglas Bryant, president and chief executive officer, will present in a fireside chat format scheduled for 11:35 a.m. ET / 8:35 a.m. PT.
Interested parties can access the live webcast and replay on the “Events & Presentations” section of the “Investor Relations” page of QuidelOrtho’s website at https://ir.quidelortho.com/.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
Ranked among the world’s largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.
The Company’s comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most. Inspired by a spirit of service, QuidelOrtho is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference. For more information, please visit www.quidelortho.com.
